A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Operable Head and Neck Cancer.
Phase of Trial: Phase 0
Latest Information Update: 04 May 2018
At a glance
- Drugs ABY 029 (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 29 Apr 2018 Planned End Date changed from 1 Dec 2018 to 31 Dec 2019.
- 29 Apr 2018 Planned primary completion date changed from 30 Sep 2018 to 1 Jun 2019.
- 29 Apr 2018 Status changed from not yet recruiting to recruiting.